Please try another search
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company’s lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Name | Age | Since | Title |
---|---|---|---|
Ross L. Levine | 49 | - | Member of Scientific Advisory Board |
Barbara A. Kosacz | 62 | 2021 | Independent Director |
Elizabeth P. Bhatt | 53 | 2021 | Independent Director |
Christopher B. Ehrlich | 51 | 2020 | CEO & Director |
Caroline M. Loewy | 54 | 2021 | Independent Director |
Brian G. Atwood | 68 | 2021 | Independent Chairman of the Board |
Robert L. Garnick | 71 | - | Member of Scientific Advisory Board |
Adam Knight | - | - | Member of Scientific Advisory Board |
Rachel Wallach Humphrey | 60 | - | Member of Scientific Advisory Board |
Michael Dyszel | - | - | Member of Scientific Advisory Board |
Jeremy Goldberg | - | - | Chairman of Scientific Advisory Board |
Mike Hodges | - | - | Member of Scientific Advisory Board |
Stephen T. Worland | 64 | 2012 | CEO, President & Director |
Brian M. Gallagher | 52 | 2021 | Independent Chairman |
Jennifer A. Doudna | 59 | - | Member of Clinical & Scientific Advisory Board |
Joan S. Brugge | - | - | Member of Clinical & Scientific Advisory Board |
Kevan M. Shokat | - | - | Co-Founder and Member of Clinical & Scientific Advisory Board |
Barbara J. Klencke | 66 | 2021 | Independent Director |
Kristen Harrington-Smith | 50 | 2022 | Independent Director |
Neal Rosen | 73 | - | Member of Clinical & Scientific Advisory Board |
Davide Ruggero | - | - | Co-Founder and Member of Clinical & Scientific Advisory Board |
Kapil Dhingra | 64 | - | Member of Clinical & Scientific Advisory Board |
Robert J. Schneider | - | - | Member of Clinical & Scientific Advisory Board |
Sarat Chandarlapaty | - | 2023 | Member of Clinical & Scientific Advisory Board |
Funda Meric-Bernstam | - | - | Member of Clinical & Scientific Advisory Board |
Christopher B. Ehrlich | 53 | 2021 | Independent Director |
Elizabeth P. Bhatt | 55 | 2021 | Independent Director |
Caroline M. Loewy | 56 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review